---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References"
description: "Reference list for the formulary evidence report on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis. 220 cited documents."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References

<a id="references"></a>

## 5 References

1. [Abdeen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449014/)
2. [Aetna Wegovy precertification policy (2026)](https://www.aetna.com/products/rxnonmedicare/data/2026/Wegovy%20PA%20with%20Limit%204774-C%2008-2026%20v2.html)
3. [Aggio et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842270/)
4. [Akbari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10827505/)
5. [Alaska Medicaid Rezdiffra criteria (2026)](https://health.alaska.gov/media/p0fbdtwy/rezdiffra_criteria_2026.pdf)
6. [Alp et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12520227/)
7. [Altimmune PERFORMA initiation release (2026)](https://altimmune.gcs-web.com/node/17931)
8. [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)
9. [Aminian et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8587225/)
10. [Angulo et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4516664/)
11. [Augusto et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/)
12. [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)
13. [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)
14. [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)
15. [Boubia et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29446942/)
16. [Boursier et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40107637/)
17. [Boyer-Diaz et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33278455/)
18. [Caussy et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12635880/)
19. [CDC FastStats chronic liver disease and cirrhosis (2026)](https://www.cdc.gov/nchs/fastats/liver-disease.htm)
20. [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)
21. [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/)
22. [Cigna Rezdiffra prior authorization policy (2026)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_852_coveragepositioncriteria_hepatology_rezdiffra_pa.pdf)
23. [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)
24. [ClinicalTrials.gov NCT03008070 API record](https://clinicaltrials.gov/api/v2/studies/NCT03008070)
25. [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)
26. [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)
27. [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)
28. [ClinicalTrials.gov NCT03866369](https://clinicaltrials.gov/study/NCT03866369)
29. [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)
30. [ClinicalTrials.gov NCT04849728 version 1](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=1)
31. [ClinicalTrials.gov NCT04849728 version 15](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=15)
32. [ClinicalTrials.gov NCT04849728 version 16](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=16)
33. [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)
34. [ClinicalTrials.gov NCT05232071 API record](https://clinicaltrials.gov/api/v2/studies/NCT05232071)
35. [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)
36. [ClinicalTrials.gov NCT06126562](https://clinicaltrials.gov/study/NCT06126562)
37. [ClinicalTrials.gov NCT06215716](https://clinicaltrials.gov/study/NCT06215716)
38. [ClinicalTrials.gov NCT06318169](https://clinicaltrials.gov/study/NCT06318169)
39. [ClinicalTrials.gov NCT06594523](https://clinicaltrials.gov/study/NCT06594523)
40. [ClinicalTrials.gov NCT06632444](https://clinicaltrials.gov/study/NCT06632444)
41. [ClinicalTrials.gov NCT07165028](https://clinicaltrials.gov/study/NCT07165028)
42. [ClinicalTrials.gov NCT07221227](https://clinicaltrials.gov/study/NCT07221227)
43. [ClinicalTrials.gov NCT07795164](https://clinicaltrials.gov/study/NCT07795164)
44. [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)
45. [Cusi et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27322798/)
46. [Cusi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35569886/)
47. [David et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2692572/)
48. [Davison et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32610115/)
49. [Duell et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35418240/)
50. [Dulai et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5397356/)
51. [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/)
52. [EU Clinical Trials Information System 2023-508248-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-508248-23-00)
53. [EU Clinical Trials Information System 2025-524385-18-00](https://euclinicaltrials.eu/ctis-public/view/2025-524385-18-00)
54. [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)
55. [European Medicines Agency NASH reflection paper (2024)](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-non-alcoholic-steatohepatitis-nash_en.pdf)
56. [FDA (2018)](https://www.fda.gov/media/119044/download)
57. [FDA (2025)](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-accepts-proposal-reasonably-likely-surrogate-endpoint-mash-all-cause-mortality-or-liver-related)
58. [Fishman et al. (2024a)](https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2393952)
59. [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/)
60. [Francque et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33038502/)
61. [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)
62. [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)
63. [Friedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6553468/)
64. [Gordon et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7327220/)
65. [Griffel et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD23-PNPLA3_V1.0_20231013.pdf)
66. [GSK efimosfermin Breakthrough Therapy and PRIME designation release (2026)](https://www.gsk.com/en-gb/media/press-releases/gsk-s-investigational-liver-therapy-efimosfermin-receives-us-fda-breakthrough-therapy/)
67. [Guo et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42702283/)
68. [Harrison et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37802088/)
69. [Harrison et al. (2024)](https://www.nejm.org/doi/full/10.1056/NEJMoa2309000)
70. [Holleboom et al. (2026)](https://inventivapharma.com/wp-content/uploads/Metabolic-Benefits-of-Lanifibranor-in-Patients-With-and-Without-Type-2-Diabetes_ParisMASH_poster.pdf)
71. [Huang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40050362/)
72. [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)
73. [ICER Final Policy Recommendations, NASH (2023)](https://icer.org/wp-content/uploads/2023/05/NASH_Policy-Recs_Final.pdf)
74. [Inventiva AASLD 2025 abstracts release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-AASLD-Abstracts-2025-EN-10-07-2025-1.pdf)
75. [Inventiva AASLD 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/INVENTIVA-AALSD-Abstracts-PR-EN-10.6.2026-1.pdf)
76. [Inventiva Breakthrough Therapy designation release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-Breakthrough-Therapy-Designation-EN-12-10-20.pdf)
77. [Inventiva clinical development changes release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Changes-clinical-development-of-lanifibranor-EN-01-04-2023.pdf)
78. [Inventiva CTTQ China IND release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-IND-Lanifibranor-China-EN-05-25-2023.pdf)
79. [Inventiva CTTQ milestone release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-CTTQ-milestone-EN-07-07-2025.pdf)
80. [Inventiva debt and equity financing release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Debt-and-Equity-EN-06-02-2026.pdf)
81. [Inventiva EASL Congress 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Abstracts-EASL-2026-EN-05-13-2026.pdf)
82. [Inventiva EASL SLD 2025 abstract release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-EASL-SLD-Abstract-01-22-2025.pdf)
83. [Inventiva Fast Track compensated cirrhosis release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Fast-Track-EN-21092021.pdf)
84. [Inventiva Fast Track designation release (2019)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-FDA-Fast-Track-EN-26092019-VF.pdf)
85. [Inventiva fifth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-5th-DMC-NATiV3-EN-10-30-2024-1.pdf)
86. [Inventiva first half 2022 results announcement (2022)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-H1-2022-EN-22092022-FINAL-2-1.pdf)
87. [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)
88. [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)
89. [Inventiva fourth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-4th-DMC-NATiV3-EN-05-16-2024.pdf)
90. [Inventiva full year 2025 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-results-2025-EN-03-30-2026-1.pdf)
91. [Inventiva Hepalys license release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Japan-Licensing-Agreement-EN-09-20-2023-1.pdf)
92. [Inventiva Hepalys phase 1 initiation release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Phase-1-Hepalys-Pharma-EN-02-20-2025.pdf)
93. [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)
94. [Inventiva LEGEND AASLD late-breaker release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-AASLD-Late-Breaker-EN-11-15-2024.pdf)
95. [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)
96. [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)
97. [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)
98. [Inventiva NATiV3 and financial update release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-and-fiancial-situation-updates-EN-07-05-2024.pdf)
99. [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf)
100. [Inventiva NATiV3 enrollment completion release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-End-of-Patient-Randomization-EN-04-01-2025.pdf)
101. [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)
102. [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)
103. [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf)
104. [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)
105. [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)
106. [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf)
107. [Inventiva Paris MASH 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/INVENTIVA-Paris-MASH-Poster-Presentations-EN-9.8.26.pdf)
108. [Inventiva preliminary full year 2023 results announcement (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-2023-Revenue-et-Cash-EN-02-15-2024-final-1.pdf)
109. [Inventiva Sino Biopharm license release (2022)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-Sino-Biopharm-Licensing-Agreement-EN-21-09-2022-1.pdf)
110. [Inventiva structured financing release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Project-Sulphur-EN-10-13-2024-_Version-finale.pdf)
111. [Inventiva third NATiV3 DMC release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-3rd-DMC-NATiV3-EN-12-04-2023.pdf)
112. [Inventiva third quarter 2025 results announcement (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Q3-2025-CA-Cash-EN-11-21-2025.pdf)
113. [Inventiva University of Florida trial topline release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Cusi-Lani-Topline-Results-EN-06132023-1.pdf)
114. [Javanbakht et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9929016/)
115. [Joszt (2024)](https://www.ajmc.com/view/fda-approves-resmetirom-first-treatment-for-nash-with-liver-fibrosis)
116. [Kamata et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10451623/)
117. [Kanwal et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6279617/)
118. [Kanwal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8819923/)
119. [Kim et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12016658/)
120. [Kim et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832100/)
121. [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)
122. [Lassailly et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32553765/)
123. [Lazarus et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12593099/)
124. [Lazarus et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12589856/)
125. [Le et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9597215/)
126. [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/)
127. [Le et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11742522/)
128. [Le et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12180822/)
129. [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232657/)
130. [Lefere et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32360434/)
131. [Lin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12135075/)
132. [Loomba et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12168897/)
133. [Loomba et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10718287/)
134. [Loomba et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38856224/)
135. [Loomba et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39396529/)
136. [Luthra and Sheth (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11787050/)
137. [Madrigal Pharmaceuticals Colorado price disclosure (2026)](https://www.madrigalpharma.com/wp-content/uploads/2026/10/Resmetirom-Price-Transparency-by-State-Form-Colorado-Oct-2026.pdf)
138. [Madrigal Pharmaceuticals Connecticut price disclosure, January 2026 (2026)](https://www.madrigalpharma.com/wp-content/uploads/2026/02/Resmetirom-Price-Transparency-by-State-Form-Connecticut-Jan-2026.pdf)
139. [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)
140. [Mahady et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22707355/)
141. [Mangia and Valenti (2025)](https://pubmed.ncbi.nlm.nih.gov/40815181/)
142. [Mantovani et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34555346/)
143. [Mantovani et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/33303564/)
144. [Mantovani et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/33685968/)
145. [Marquardt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019595/)
146. [McGovern et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13694306/)
147. [Mironova et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42728029/)
148. [Mittal et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12425555/)
149. [NCQA](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/glycemic-status-assessment-for-patients-with-diabetes-gsd/)
150. [Newsome et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066580/)
151. [Ng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10792524/)
152. [Njei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13126990/)
153. [Noureddin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41237796/)
154. [Noureddin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41655584/)
155. [Novo Nordisk (2026)](https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916505)
156. [Novo Nordisk Akero acquisition completion release (2025)](https://akerotx.com/wp-content/uploads/2025/12/pr251209-akero-closing.pdf)
157. [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)
158. [NovoCare MASH list price (2025)](https://www.novocare.com/mash/resources/explaining-list-price.html)
159. [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)
160. [PA Health and Wellness resmetirom clinical policy (2025)](https://www.pahealthwellness.com/content/dam/centene/Pennsylvania/policies/pharmacy-policies/Resmetirom_Rezdiffra_v1.2025.pdf)
161. [Papadimopoulos et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43039875/)
162. [Patel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11869966/)
163. [Patel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094816/)
164. [Payne et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9833447/)
165. [Prime Therapeutics HCSC resmetirom program summary (2026)](https://www.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/HCSC/Program_Summaries/HCSC_Resmetirom_PAQL_ProgSum.pdf)
166. [Promrat et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2799538/)
167. [Pulaski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410674/)
168. [Rautou et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12142333/)
169. [Ravela et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970881/)
170. [Riazi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35798021/)
171. [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)
172. [Rinella et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653297/)
173. [Rinella et al. (2026a)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-MASH-TAG-2026-final-version.pdf)
174. [Rinella et al. (2026b)](https://inventivapharma.com/wp-content/uploads/ADP-and-Weight-Gain-Correlation-Poster_EASL2624.pdf)
175. [Roche 89bio merger agreement release (2025)](https://www.roche.com/media/releases/med-cor-2025-09-18)
176. [Roche 89bio tender offer release (2025)](https://www.roche.com/media/releases/med-cor-2025-10-30)
177. [Sabatini and Gastaldelli (2025)](https://pubmed.ncbi.nlm.nih.gov/40089070/)
178. [Sagimet Biosciences strategic and corporate updates release (2026)](https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-provides-strategic-and-corporate-updates)
179. [Sanyal et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928471/)
180. [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/)
181. [Sanyal et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38847460/)
182. [Sanyal et al. (2025)](https://www.nejm.org/doi/full/10.1056/NEJMoa2413258)
183. [Sayiner et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5013331/)
184. [Sayiner et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5300028/)
185. [Schneider et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12285740/)
186. [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)
187. [Shuaibi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12271776/)
188. [Simon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185553/)
189. [Singh et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4208976/)
190. [Souza et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12614381/)
191. [Sterling et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/38489523/)
192. [Sterling et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/38489518/)
193. [Takeda Pharmaceuticals ACTOS prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf)
194. [Tan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9718369/)
195. [Tapper et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36866575/)
196. [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/)
197. [Taylor et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32027911/)
198. [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)
199. [Verrastro et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37088093/)
200. [Vilar-Gomez et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25865049/)
201. [Wallace et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39832655/)
202. [Wettstein et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5678909/)
203. [WHO Drug Information (2016)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl116.pdf)
204. [Wong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8500367/)
205. [Younossi et al. (2016a)](https://pubmed.ncbi.nlm.nih.gov/26707365/)
206. [Younossi et al. (2016b)](https://pubmed.ncbi.nlm.nih.gov/27543837/)
207. [Younossi et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28211165/)
208. [Younossi et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30180285/)
209. [Younossi et al. (2019b)](https://pubmed.ncbi.nlm.nih.gov/30779990/)
210. [Younossi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7603531/)
211. [Younossi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8279457/)
212. [Younossi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9418497/)
213. [Younossi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026948/)
214. [Younossi et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39373093/)
215. [Younossi et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11835563/)
216. [Younossi et al. (2025c)](https://pubmed.ncbi.nlm.nih.gov/39879587/)
217. [Younossi et al. (2025d)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12277723/)
218. [Younossi et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/40674288/)
219. [Younossi et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41950980/)
220. [Younossi et al. (2026c)](https://pubmed.ncbi.nlm.nih.gov/42925568/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
